Skip to Content

Insights From Our Labs to Yours

Covance Blog

  • Home
  • Industry
    • Device
    • Drug
    • Chemical
    • Crop
  • Phase
    • Discovery
    • Preclinical/Nonclinical
    • Phase I-IIa
    • Phase IIb-III
    • Pilot
    • Pivotal
    • Formulation, Packaging, etc.
  • Molecule Type
    • Biologics
    • Small Molecules
    • Biosimilars
    • Biomarkers
    • Cell/Gene Therapies
  • Data/Informatics
    • SEND
    • Modeling
    • Patient Recruitment
    • Xcellerate
  • About Us
    • Careers and Culture
    • Contact Us
    • Covance.com

Regulatory Agencies

Home / Regulatory / Regulatory Agencies
Share

A comparison of FDA, EMA & PMDA regulatory guidance for in vitro drug-drug interaction (DDI) assessments

by Covance Inc.updated on Monday, June 29, 2020Monday, June 29, 2020

This online whitepaper article explores the 2020 regulatory changes in U.S. FDA guidance1 and recommendations, compared to existing EU EMA2 and Japanese PMDA3 guidance for in in vitro drug–drug interaction (DDI) assessments.

Copyright © 2020 Covance Inc. All rights reserved.